For example, several PP2A-activating drugs (PADs), such as OP449 and FTY720 (a SET antagonist), were reported to enhance a cell death-inducing effect of FLT3 TKIs in FLT3-ITD-driven AML cell lines and primary AML cells [22,23]. Here, SET is linked to acute myeloid leukemia.